Pre-emptive pangenotypic direct acting antiviral therapy in donor HCV-positive to recipient HCV-negative heart transplantation: an open-label study

2019 Durand, 2018, The drug overdose epidemic and deceased-donor transplantation in the United States: a national registry study, Ann Intern Med, 168, 702, 10.7326/M17-2451 Levitsky, 2017, The American Society of Transplantation Consensus Conference on the Use of Hepatitis C Viremic Donors in Solid Organ Transplantation, Am J Transplant, 17, 2790, 10.1111/ajt.14381 Fong, 2009, Impact of hepatitis C infection on outcomes after heart transplantation, Transplantation, 88, 1137, 10.1097/TP.0b013e3181bd3e59 Ong, 1999, Outcome of de novo hepatitis C virus infection in heart transplant recipients, Hepatology, 30, 1293, 10.1002/hep.510300519 Zein, 1995, Prevalence and outcome of hepatitis C infection among heart transplant recipients, J Heart Lung Transplant, 14, 865 Kim, 2011, A concise review of hepatitis C in heart and lung transplantation, Can J Gastroenterol, 25, 445, 10.1155/2011/947838 File, 2003, Allograft transmission of hepatitis C virus infection from infected donors in cardiac transplantation, Transplantation, 76, 1096, 10.1097/01.TP.0000088663.76640.C9 Gasink, 2006, Hepatitis C virus seropositivity in organ donors and survival in heart transplant recipients, JAMA, 296, 1843, 10.1001/jama.296.15.1843 Haji, 2004, Donor hepatitis-C seropositivity is an independent risk factor for the development of accelerated coronary vasculopathy and predicts outcome after cardiac transplantation, J Heart Lung Transplant, 23, 277, 10.1016/S1053-2498(03)00148-7 Marelli, 2002, Hepatitis C-positive donors in heart transplantation, Am J Transplant, 2, 443, 10.1034/j.1600-6143.2002.20508.x Pereira, 1991, Transmission of hepatitis C virus by organ transplantation, N Engl J Med, 325, 454, 10.1056/NEJM199108153250702 Fagiuoli, 2001, HBV and HCV infections in heart transplant recipients, J Heart Lung Transplant, 20, 718, 10.1016/S1053-2498(01)00255-8 Pfau, 2000, Hepatitis C transmission and infection by orthotopic heart transplantation, J Heart Lung Transplant, 19, 350, 10.1016/S1053-2498(00)00062-0 Foster, 2005, Treatment of HCV infection with pegylated interferons, Curr Hepatitis Rep, 4, 49, 10.1007/s11901-005-0014-4 Kilic, 2014, Donor selection in heart transplantation, J Thorac Dis, 6, 1097 Berenguer, 2008, Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation, Am J Transplant, 8, 679, 10.1111/j.1600-6143.2007.02126.x Berenguer, 2008, Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin, J Hepatol, 49, 274, 10.1016/j.jhep.2008.05.002 Asselah, 2016, Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives, Liver Int, 36, 47, 10.1111/liv.13027 Gottlieb, 2018, The new direct antiviral agents and hepatitis C in thoracic transplantation: impact on donors and recipients, Curr Transplant Rep, 5, 145, 10.1007/s40472-018-0192-y Shah, 2017, Successful treatment of donor-derived hepatitis C viral infection in three transplant recipients from a donor at increased risk for bloodborne pathogens, Transpl Infect Dis, 19, 10.1111/tid.12660 Khan, 2017, Successful lung transplantation from hepatitis C positive donor to seronegative recipient, Am J Transplant, 17, 1129, 10.1111/ajt.14137 Saberi, 2018, Utilization of hepatitis C virus RNA-positive donor liver for transplant to hepatitis C virus RNA-negative recipient, Liver Transplant, 24, 140, 10.1002/lt.24838 Goldberg, 2017, Trial of transplantation of HCV-infected kidneys into uninfected recipients, N Engl J Med, 376, 2394, 10.1056/NEJMc1705221 Schlendorf, 2018, Early outcomes using hepatitis C-positive donors for cardiac transplantation in the era of effective direct-acting anti-viral therapies, J Heart Lung Transplant, 37, 763, 10.1016/j.healun.2018.01.1293 Durand, 2018, Direct-acting antiviral prophylaxis in kidney transplantation from hepatitis C virus-infected donors to noninfected recipients: an open-label nonrandomized trial, Ann Intern Med, 168, 533, 10.7326/M17-2871 Woolley, 2019, Heart and lung transplants from HCV-infected donors to uninfected recipients, N Engl J Med, 380, 1606, 10.1056/NEJMoa1812406 McLean, 2019, Transplanting hepatitis C virus-infected hearts into uninfected recipients: a single-arm trial, Am J Transplant, 10.1111/ajt.15311 Gane, 2017, Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment, N Engl J Med, 377, 1448, 10.1056/NEJMoa1704053 Feld, 2015, Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection, N Engl J Med, 373, 2599, 10.1056/NEJMoa1512610 Irwin, 2017, Utilization of increased risk for transmission of infectious disease donor organs in solid organ transplantation: retrospective analysis of disease transmission and safety, Transpl Infect Dis, 19, 10.1111/tid.12791 Feld J, Humar A, Singer L, et al. Lung transplantation from HCV-infected donors to HCV-uninfected recipients. Hepatology 68 (suppl 1): 223 (abstr). Wadei, 2019, Transplantation of HCV-infected organs into uninfected recipients: advance with caution, Am J Transplant, 19, 960, 10.1111/ajt.15152 Chhatwal, 2018, Transplanting HCV-positive livers into HCV-negative patients with preemptive antiviral treatment: a modeling study, Hepatology, 67, 2085, 10.1002/hep.29723 Bethea, 2019, Cost effectiveness of transplanting HCV-infected livers into uninfected recipients with preemptive antiviral therapy, Clin Gastroenterol Hepatol, 17, 739, 10.1016/j.cgh.2018.08.042 Zimmermann, 2017, Reply to: “Negotiating better discounts for DAA therapy is critical to achieve HCV elimination by 2030”, J Hepatol, 67, 420, 10.1016/j.jhep.2017.03.033